GNTA
Genenta Science SpA
NASDAQ · Healthcare · Biotechnology · IT
$0.70
−7.74%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +35.8%
- EBIT
- +36.7%
- EPS
- +32.7%
- Free cash flow
- -23.7%
- Operating cash flow
- -23.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +36.7%
- EBIT
- +37.8%
- Net income
- +32.6%
- EPS
- +32.7%
- Free cash flow
- -10.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025